Klinik für Urologie und Kinderurologie

Studien zur Erkrankung der Prostata

A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

An open-label, single arm, roll-over study to provide continued treatment
with darolutamide in participants who were enrolled in previous Bayer-sponsored studies

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of
radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients
with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing
on/after one line of NAH.

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 6-month Formulation Administered Subcutaneously in Participants With Locally Advanced and/or Metastatic Prostate Cancer Previously Treated and Castrated With a GnRH Analogue

Studien-Status: wirdgeöffnet

Weitere Informationen finden Sie hier.

 
 
 
 

Kontakt

Ansgar Nehus (Ltd. study nurse)
Michael Grenzebach (study nurse)
Anika Kunz (study nurse)
Nadine Rosenow (study nurse)

Terminvereinbarung
Montag bis Donnerstag: 10 - 14 Uhr
E uroonkologie(at)­ukmuenster(dot)­de
T +49 (0)251- 83 48 12 6

 

IN NOTFÄLLEN
T +49 (0)251- 83 47 44 6 oder
T +49 (0)251- 83 48 00 1

Dr. med. Katrin Schlack, FEBU
OA für den Bereich Uroonkologie
Prüfärztin
E-Mail: Katrin.Schlack(at)­ukmuenster(dot)­de